Accelerate Productivity in 2025

Reignite Growth Despite the Global Slowdown
DOWNLOAD YOUR 25 PAGE TOOLKIT

Executive Summary: Which are the Top 10 Regenerative Medicine Companies & Startups to Watch?

  1. VivoTex (US): Produces melt electrowriting (MEW) scaffolds for tissue repair. Its designs support microtissue assembly, neural growth, and uniform skin regeneration.
  2. Tolemy Bio (UK): Builds an AI-driven platform for custom media design. It tailors cell culture formulations to boost cell and gene therapy outcomes.
  3. TQ Therapeutics (Germany): Offers a modular gene delivery platform. It enables rapid, patient-specific therapies without centralized manufacturing.
  4. Trogenix (UK): Develops viral immunotherapy using synthetic super-enhancers (SSEs). Its tech delivers targeted gene control in disease-specific cells.
  5. Quixotix (India): Creates 3D bioprinters and custom bioinks. Its systems support on-demand tissue fabrication for personalized medicine.
  6. Immitra Bio (Switzerland): Combines CRISPR-Cas9 with stem cells for in-vivo gene editing. It treats rare diseases through durable genetic correction.
  7. BE Therapeutics (US): Engineers structured brain tissues that mimic natural networks. The implants restore lost neurological function after damage.
  8. MesencHyal-T (Argentina): Provides AI-powered stem cell therapies for bone regeneration. It boosts healing with hyaluronic acid and scalable production.
  9. Cell2Bio (Sweden): Offers a 3D cell culture platform using hydrogel matrices. It supports oncology research and personalized drug testing.
  10. Shinobi Therapeutics (US): Builds immune-evasive iPS cell therapies. Its platform delivers off-the-shelf solutions for cancer, diabetes, and autoimmune conditions.

Global Startup Heat Map highlights Emerging Regenerative Medicine Companies & Startups to Watch

Through the Big Data & Artificial Intelligence (AI)-powered StartUs Insights Discovery Platform, covering over 7M+ startups, 20K+ technology trends plus 150M+ patents, news articles & market reports, we identified 700+ regenerative medicine startups.

The Global Startup Heat Map below highlights emerging regenerative medicine startups you should watch in 2026, as well as the geo-distribution of the 700+ startups & scaleups we analyzed for this research.

According to our data, we observe high startup activity in the US and the UK, followed by India. The top 5 Startup Hubs for Regenerative Medicine Startups are London, Cambridge, Boston, New York City, and San Diego.

 

 

Explore Emerging Regenerative Medicine Startups to Watch [2026]

We hand-picked startups to showcase in this report by filtering for their technology, founding year, location, funding, and other metrics. These emerging regenerative medicine startups work on solutions ranging from in-vivo genetic medicine platforms and 3D bioprinters for tissue engineering to multi-cell type structured brain tissues and IPS cell therapies.

1. VivoTex

  • Founding Year: 2024
  • Location: Newberg, US
  • Use For: Melt Electrowriting (MEW) Microfiber Scaffolds

US-based startup VivoTex produces melt electrowriting (MEW) microfiber scaffolds for regenerative medicine. It uses a high-precision additive manufacturing process that extrudes molten polymer through a charged spinneret and arranges micron-scale fibers into tailored architectures.

The collection of designs includes box scaffolds that securely hold spheroids and organoids to enable microtissue assembly, aligned scaffolds that guide muscle and neural growth, and isotropic scaffolds that enable uniform skin regeneration.

Moreover, they deliver consistent fiber resolution and mechanical robustness to maintain scaffold integrity under cellular remodeling. VivoTex thus provides researchers with application-tuned scaffolds that streamline model development, enhance cell integration, and advance translational workflows in tissue repair.

2. Tolemy Bio

  • Founding Year: 2024
  • Location: Cambridge, UK
  • Use For: Custom Media Design Platform
  • Prominent Partnerships: Qkine

UK-based startup Tolemy Bio engineers cell performance through custom media design to enhance cell and gene therapy. It maps metabolite consumption and cell performance metrics to characterize the metabolic state of each process.

Further, it leverages AI-driven optimization to tailor formulations for immune cell therapies, stem cell therapies, and gene therapies.

Moreover, this solution delivers small-batch media within weeks and subjects each batch to rigorous quality control to enable complex cell phenotypes and meet critical quality features.

3. TQ Therapeutics

  • Founding Year: 2023
  • Location: Planegg, Germany
  • Use For: Modular Target Cell-specific Modification Platform
  • Prominent Partnerships: Pantherna Therapeutics

German startup TQ Therapeutics develops a modular target cell-specific modification platform that accelerates regenerative medicine. This method uses extra-corporeal gene therapy. However, it keeps the benefits of autologous cell therapy, where patients receive treatments made out of their own cells.

It creates genetically modified immune cells and delivers cell therapy directly to the patient, thereby avoiding the complicated and costly steps of centralized production. This solution unlocks the full potential of autologous cell therapies for treating rare autoimmune conditions and cancers.

4. Trogenix

  • Founding Year: 2023
  • Location: Edinburgh, UK
  • Use For: Synthetic Super-Enhancers-based Viral Immunotherapy
  • Funding: Launched with GBP 15 million in seed funding
  • Prominent Partnerships: Viralgen

UK-based startup Trogenix specializes in viral immunotherapy that uses synthetic super-enhancers (SSEs), which are engineered DNA elements that are only activated in diseased cell states.

These elements act as docking stations for transcription factors in aggressive cells and enable precise gene control. The platform integrates genomics, profiling, bioinformatics, and machine learning to identify those factors and design enhancer fragments.

The technology tracks disease-specific factor patterns and scales treatment to match disease burden. Moreover, it combines targeted cell killing with immune activation and shuts off when cells lose diseased traits. Trogenix applies this to cancer and extends it to regenerative medicine, tissue repair, and age-related conditions.

5. Quixotix

Indian startup Quixotix makes a 3D bioprinter, Clutch 1, and bioinks for tissue engineering. It employs precision extrusion mechanisms and proprietary hydrogel formulations to layer living cells and support materials within sterile, temperature-controlled environments.

Moreover, it integrates HEPA-filtered enclosures and precise print heads in its desktop system and a lightweight, modular handheld unit with adjustable flow control for on-demand tissue fabrication.

This way, Quixotix accelerates regenerative medicine by providing bioprinting tools that enable tissue regeneration, expedite drug development, and address organ shortages.

 

Want to Explore 700+ Regenerative Medicine Startups & Scaleups?

Request Sample Database

 

6. Immitra Bio

Swiss startup Immitra Bio develops an in-vivo genetic medicine platform by combining hematopoietic stem cells with CRISPR-Cas9 gene editing. This enables precise and durable gene modifications within blood stem cells, thereby enabling treatments for rare diseases with high unmet medical needs.

The platform leverages HSC self-renewal and differentiation alongside the HematoGen gene-integration system to continuously produce functional proteins and address genetic root causes. Moreover, it scales across multiple rare diseases that lack approved therapies and serves both pediatric and adult patients.

7. BE Therapeutics

US-based startup BE Therapeutics engineers multi-cell type structured brain tissue to replace damaged neocortical tissue. It combines nerve and support cells on a scaffold that mimics natural brain structure and encourages the tissue to mature and connect with blood vessels after transplantation.

Moreover, the engineered tissue follows developmental cues to integrate with host circuits and transmit functional signals. Its methodology extends to replace damaged neocortical regions and advances toward spinal cord applications.

BE Therapeutics thus provides a regenerative solution that reverses central nervous system damage and restores durable neurological function.

8. MesencHyal-T

Argentinian startup MesencHyal-T creates AI-powered cellular regenerative therapies for bone injuries. It combines allogeneic mesenchymal stem cells with hyaluronic acid extracted from umbilical cord tissue through an ex vivo scalable production process. This process uses machine learning to standardize cell expansion and enhance osteogenic potential.

 

 

Moreover, the startup forges partnerships with hospitals and research centers to accelerate clinical deployment. This way, MesencHyal-T reduces time to restore bone function, complications, and also predicts treatment outcomes.

9. Cell2Bio

  • Founding Year: 2023
  • Location: Stockholm, Sweden
  • Use For: 3D Cell Culture Platform

Swedish startup Cell2Bio provides a 3D cell culture platform that enables cells to grow in a three-dimensional environment, allowing cells to form 3D spheroids replicating tumor architecture. It leverages hydrogel matrices and hanging-drop techniques within standard plate formats to ensure straightforward operation.

Moreover, the system employs sustainable materials and accommodates custom surface coatings to align with diverse research needs. Cell2Bio thus facilitates oncology drug discovery and personalized medicine by enabling precise dose optimization, treatment monitoring, and predictive insights.

10. Shinobi Therapeutics

  • Founding Year: 2023
  • Location: San Francisco, US
  • Use For: Induced Pluripotent Stem (iPS) Cell Therapies
  • Funding: Launches with completion of USD 51 million Series A
  • Prominent Partnerships: Panasonic, Anocca AB

US-based startup Shinobi Therapeutics develops immune-evasive iPS cell therapies for regenerative medicine applications such as tissue repair, tumor clearance, and immune modulation. It uses its platform to transform a single-clone iPSC source into off-the-shelf therapeutic cells by integrating plug-and-play antigen specificity.

Simultaneously, it incorporates genetic edits that prevent detection by T cells, innate immune cells, and antibodies while boosting survival in hostile microenvironments.

These engineered cells move to sites of injury or disease and replace dysfunctional cells. Shinobi Therapeutics thus enables broader access to regenerative treatments for solid tumors, autoimmune disorders, as well as diabetes.

Discover All Emerging Pharma Startups

The pharma startups showcased in this report are only a small sample of all startups we identified through our data-driven startup scouting approach. Download our free Pharma Innovation Report for a broad overview of the industry or get in touch for quick & exhaustive research on the latest technologies & emerging solutions that will impact your company in 2026!